Dr. Paul Oberstein, MD
Claim this profileNYU Langone Health
Studies Pancreatic Cancer
Studies Adenocarcinoma
18 reported clinical trials
46 drugs studied
About Paul Oberstein, MD
Education:
- Received an MD (Doctor of Medicine) from New York University School of Medicine in 2009.
Experience:
- Serves as Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Perlmutter Cancer Center, NYU Langone Health.
- Holds the position of Clinical Director of the Lymphoma Program at Perlmutter Cancer Center, NYU Langone Health.
Area of expertise
1Pancreatic Cancer
Stage IV
Stage III
BRCA1 positive
2Adenocarcinoma
Stage IV
BRCA1 positive
BRCA2 positive
Affiliated Hospitals
Clinical Trials Paul Oberstein, MD is currently running
Olaparib
for Pancreatic Cancer
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Recruiting0 awards Phase 232 criteria
Nous-209 Vaccine
for Metastatic Cancer
Ref: Protocol v9.0, dated 7Nov2023. NOUS-209-01 is a multicenter, open-label, multiple cohorts, clinical study, designed to evaluate safety, tolerability, and immunogenicity, and to detect any preliminary evidence of anti-tumor activity of Nous-209 genetic polyvalent vaccine plus pembrolizumab combination therapy in adult subjects with unresectable or metastatic deficient mismatch repair (dMMR) or MSI-H CRC, gastric, or gastro-esophageal junction (G-E junction) tumors. Nous-209 is based on a heterologous prime/boost regimen composed of the Great Ape Adenovirus GAd20-209-FSP used for priming and Modified Vaccinia virus Ankara MVA-209-FSP used for boosting. The Phase I portion of the study is a first-in-human (FIH) clinical study with a primary objective to elucidate the safety and tolerability of Nous-209 in addition to establishing the recommended Phase 2 dose (RP2D), whereas the Phase II was introduced to assess efficacy as the primary objective.
Recruiting1 award Phase 1 & 225 criteria
More about Paul Oberstein, MD
Clinical Trial Related2 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Paul Oberstein, MD has experience with
- Nab-paclitaxel
- Gemcitabine
- Ipilimumab
- Pembrolizumab
- Nivolumab
- Zimberelimab
Breakdown of trials Paul Oberstein, MD has run
Pancreatic Cancer
Adenocarcinoma
Colorectal Cancer
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Paul Oberstein, MD specialize in?
Paul Oberstein, MD focuses on Pancreatic Cancer and Adenocarcinoma. In particular, much of their work with Pancreatic Cancer has involved Stage IV patients, or patients who are Stage III.
Is Paul Oberstein, MD currently recruiting for clinical trials?
Yes, Paul Oberstein, MD is currently recruiting for 6 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Paul Oberstein, MD has studied deeply?
Yes, Paul Oberstein, MD has studied treatments such as Nab-paclitaxel, Gemcitabine, Ipilimumab.
What is the best way to schedule an appointment with Paul Oberstein, MD?
Apply for one of the trials that Paul Oberstein, MD is conducting.
What is the office address of Paul Oberstein, MD?
The office of Paul Oberstein, MD is located at: NYU Langone Health, New York, New York 11735 United States. This is the address for their practice at the NYU Langone Health.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.